Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
Pyxis Oncology (Nasdaq: PYXS) appointed Alex Kane as Senior Vice President, Investor Relations & Capital Markets, effective October 9, 2025. Kane joins with 20 years of life‑science investor relations and equity capital markets experience, most recently at Guggenheim Securities.
His background includes investor relations and communications roles at Praxis Precision Medicines and PTC Therapeutics and prior leadership at W2O Group, Nasdaq, and Thomson Reuters. Kane holds an MBA in Finance and Entrepreneurship from NYU Stern and a BA in International Political Economy from Colorado College. Management highlights cite his experience with IPOs, secondary offerings, and investor engagement as relevant to advancing Pyxis Oncology’s clinical programs and upcoming milestones.
Pyxis Oncology (Nasdaq: PYXS) ha nominato Alex Kane come Senior Vice President, Investor Relations & Capital Markets, a partire dal 9 ottobre 2025. Kane porta con sé 20 anni di esperienza nelle relazioni con gli investitori nel settore life science e nei mercati di capitale azionari, provenienti più recentemente da Guggenheim Securities.
Il suo background include ruoli nelle relazioni con gli investitori e nelle comunicazioni presso Praxis Precision Medicines e PTC Therapeutics e precedenti ruoli di leadership al W2O Group, Nasdaq e Thomson Reuters. Kane possiede un MBA in Finance and Entrepreneurship da NYU Stern e una laurea in International Political Economy del Colorado College. I dirigenti evidenziano che la sua esperienza in IPO, offerte secondarie e coinvolgimento degli investitori è rilevante per far progredire i programmi clinici di Pyxis Oncology e i prossimi traguardi.
Pyxis Oncology (Nasdaq: PYXS) nombró a Alex Kane como Vicepresidente Senior de Relaciones con Inversores y Mercados de Capital, con efecto a partir del 9 de octubre de 2025. Kane se une con 20 años de experiencia en relaciones con inversores en ciencias de la vida y mercados de capital, más recientemente en Guggenheim Securities.
Su experiencia incluye roles de relaciones con inversores y comunicaciones en Praxis Precision Medicines y PTC Therapeutics, y puestos de liderazgo previos en el W2O Group, Nasdaq y Thomson Reuters. Kane posee un MBA en Finanzas y Emprendimiento de NYU Stern y una Licenciatura en Economía Política Internacional del Colorado College. La dirección destaca que su experiencia en OPIs (ofertas públicas iniciales), emisiones secundarias y participación de inversores es relevante para avanzar los programas clínicos de Pyxis Oncology y los próximos hitos.
Pyxis Oncology (Nasdaq: PYXS)가 Alex Kane를 투자자 관계 및 자본시장 수석 부사장으로 2025년 10월 9일부로 임명했습니다. Kane은 최근 Guggenheim Securities에서 근무한 생명과학 분야 투자자 관계 및 주식 시장에서의 20년의 경험을 가지고 있습니다.
그의 경력에는 Praxis Precision Medicines와 PTC Therapeutics의 투자자 관계 및 커뮤니케이션 역할, 그리고 W2O Group, Nasdaq, Thomson Reuters에서의 선임 직책이 포함됩니다. Kane은 NYU Stern에서 금융 및 창업 MBA를, 콜로라도 칼리지에서 국제정치경제학 학사를 보유하고 있습니다. 경영진은 IPO, 2차 유상매도 및 투자자 참여에 대한 그의 경험이 Pyxis Oncology의 임상 프로그램과 향후 이정표를 추진하는 데 관련이 있다고 강조합니다.
Pyxis Oncology (Nasdaq : PYXS) a nommé Alex Kane comme Vice-président sénior, Investor Relations & Capital Markets, à compter du 9 octobre 2025. Kane rejoint avec 20 ans d'expérience en relations avec les investisseurs et marchés de capitaux dans le domaine des sciences de la vie, plus récemment chez Guggenheim Securities.
Son parcours inclut des fonctions en relations investisseurs et communications chez Praxis Precision Medicines et PTC Therapeutics, ainsi que des postes de direction antérieurs chez W2O Group, Nasdaq et Thomson Reuters. Kane est titulaire d'un MBA en Finance et Entrepreneuriat de NYU Stern et d'un BAC en International Political Economy du Colorado College. La direction souligne que son expérience des introductions en bourse (IPO), des émissions secondaires et de l'engagement des investisseurs est pertinente pour faire progresser les programmes cliniques de Pyxis Oncology et les jalons à venir.
Pyxis Oncology (Nasdaq: PYXS) hat Alex Kane zum Senior Vice President, Investor Relations & Capital Markets ernannt, mit Wirkung ab dem 9. Oktober 2025. Kane kommt mit 20 Jahren Erfahrung in Investor Relations und Equity Capital Markets im Bereich der Lebenswissenschaften, zuletzt bei Guggenheim Securities.
Seinen Hintergrund umfasst Rollen in Investor Relations und Kommunikation bei Praxis Precision Medicines und PTC Therapeutics sowie frühere Führungspositionen bei W2O Group, Nasdaq und Thomson Reuters. Kane besitzt einen MBA in Finance and Entrepreneurship von der NYU Stern und einen BA in International Political Economy vom Colorado College. Das Management hebt hervor, dass seine Erfahrungen mit IPOs, Secondary Offerings und Investorenengagement relevant sind, um Pyxis Oncologys klinische Programme und die kommenden Meilensteine voranzutreiben.
Pyxis Oncology (ناسداك: PYXS) عينت Alex Kane كنائب رئيس أول للعلاقات مع المستثمرين والأسواق الرأس مالية، اعتباراً من 9 أكتوبر 2025. ينضم كين إلى الشركة وهو يمتلك 20 عاماً من الخبرة في علاقات المستثمرين في علوم الحياة وأسواق رأس المال، وكان آخرها في Guggenheim Securities.
يشمل خلفيته أدوار العلاقات مع المستثمرين والاتصالات في Praxis Precision Medicines وPTC Therapeutics، ومناصب قيادية سابقة في W2O Group وNasdaq وThomson Reuters. يحمل كين درجة MBA في التمويل وريادة الأعمال من NYU Stern وبكالوريوس في International Political Economy من Colorado College. تؤكد الإدارة أن خبرته في عمليات الطرح العام الأولي (IPOs) والعروض الثانوية ومشاركة المستثمرين ذات صلة بتقدم برامج Pyxis Oncology السريرية والتحقيق من المراحل المقبلة.
Pyxis Oncology (纳斯达克：PYXS) 已任命 Alex Kane 为高级副总裁，投资者关系与资本市场，自 2025 年 10 月 9 日起生效。Kane 具备在生命科学领域的投资者关系与股本市场方面的 20 年 经验，最近任职于 Guggenheim Securities。
他的背景还包括在 Praxis Precision Medicines 与 PTC Therapeutics 的投资者关系与传播岗位，以及在 W2O Group、Nasdaq 和 Thomson Reuters 的前任领导岗位。Kane 拥有 NYU Stern 的 金融与创业 MBA，以及科罗拉多学院的 国际政治经济学 学士学位。管理层强调，他在首次公开募股（IPO）、二次发行和投资者参与方面的经验，对推动 Pyxis Oncology 的临床项目和未来里程碑具有相关性。
- Appointment effective October 9, 2025
- 20 years of investor relations and equity capital markets experience
- Track record managing IPOs and secondary offerings
- None.
BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced the appointment of Alex Kane, MBA, as Senior Vice President, Investor Relations & Capital Markets, effective immediately.
Mr. Kane brings 20 years of experience and a proven track record in investor relations, strategic communications, and equity capital markets across the life sciences sector. He joins Pyxis Oncology from Guggenheim Securities, where he served as Vice President of Equity Capital Markets, advising biotechnology clients on financing strategies and equity transactions.
Previously, Mr. Kane held senior investor relations and communications roles at Praxis Precision Medicines and PTC Therapeutics, successfully managing IPOs, secondary offerings, and long-term investor engagement. Earlier in his career, he held leadership positions at W2O Group, NASDAQ, and Thomson Reuters, where he advised public and private life sciences companies on capital markets strategy, investor targeting, and corporate positioning.
Mr. Kane earned his MBA in Finance and Entrepreneurship from the NYU Stern School of Business and his BA in International Political Economy from Colorado College.
“Alex brings deep expertise in both investor relations and capital markets, and he is highly regarded for his ability to effectively communicate value-creation opportunities to the investment community,” said Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer of Pyxis Oncology. “His insights and strong relationships will be critical as Pyxis Oncology advances MICVO’s clinical programs and prepares for upcoming milestones.”
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical-stage company focused on defeating difficult-to-treat cancers. The Company is efficiently building therapeutics that hold the potential for monotherapy and combination indications. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), has been evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the strength of the HNSCC signal that emerged. Additionally, the Company initiated a Phase 1/2 combination study of MICVO and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors.
To learn more, visit www.pyxisoncology.com or follow us on X (formerly known as Twitter) and LinkedIn.
Pyxis Oncology Contact
Alex Kane
Senior Vice President, Investor Relations & Capital Markets
IR@pyxisoncology.com
FAQ
Who is Alex Kane and what role did he take at Pyxis Oncology (PYXS) on October 9, 2025?
How much experience does Pyxis Oncology's new IR head Alex Kane have and where did he work previously?
What expertise does Alex Kane bring that could affect PYXS investor communications?
Will Alex Kane’s appointment likely change how Pyxis Oncology (PYXS) communicates clinical milestones?
Does Alex Kane have formal finance education relevant to the PYXS role?
